ERADICATE

CANNABICS™ RCC-33

Drug candidate for the treatment
of Colorectal Cancer (CRC)

COLORECTAL
CANCER (CRC)

  • 3rd most commonly diagnosed cancer worldwide
  • 1,849,518 new cases in 2018 worldwide
  • 2nd most lethal cancer worldwide
  • 880,792 deaths in 2018 worldwide
  • 67% of treated patients survive 5 years or more
COLORECTAL<br> CANCER (CRC)
CLINICAL PATH

CLINICAL PATH

  • Preclinical POC validation (ongoing)
  • Dossier preparation for submission of Pre-IND meeting request with FDA

SYNERGISTIC INTERACTION OF RCC-33
ON COLON CANCER CELL LINES

RCC-33: >70% dead cancer cells

CANNABICS™ RCC-33
DRUG CANDIDATE FOR TREATING
COLON CANCER

  • A novel cannabinoid-based formulation
  • Formula demonstrated significant synergistic antitumor effect
    in pre clinical studies
  • No psychoactive effect
  • Patent pending
CANNABICS™ RCC-33<br>DRUG CANDIDATE FOR TREATING<br>COLON CANCER